The company delivers consistent earnings beats — four consecutive quarters each with a modest positive surprise — and trades at an undemanding forward P/E of 8.8x, but quality marginally below the minimum acceptable level, the absence of a recognized competitive moat, and a risk/reward geometry of only 4.4% upside against 8.5% downside leave the current setup unattractive for new capital despite constructive price action.
Thesis pillars
- Quality Below Minimum Threshold↑Improving
- Consistent Earnings Execution→Stable
- Attractive Valuation Vs Peers→Stable
- +1 more pillar — see the Why tab for full reasoning
The Cigna Group (CI) Stock Analysis
Range Bound setup
Healthcare · Healthcare Plans
Hold if already holding. Not a fresh buy at $282.56, but acceptable to hold if already in. Reasons: Thin upside margin: 8.7%; Negative momentum.
The Cigna Group runs two segments: Evernorth Health Services (pharmacy benefit management, specialty pharmacy, care services) and Cigna Healthcare (commercial medical plans, international health), serving 185 million customer relationships. Revenue comes from pharmacy processing... Read more
Hold if already holding. Not a fresh buy at $282.56, but acceptable to hold if already in. Reasons: Thin upside margin: 8.7%; Negative momentum. Chart setup: RSI 44 mid-range, Bollinger mid-band. Mixed signals. Hold existing position. Score 5.6/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, earnings proximity 81d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and news legal. Suitability: moderate.
About The Cigna Group
About The Cigna Group
The Cigna Group served more than 185 million customer relationships across more than 30 markets and jurisdictions as of December 31, 2025, through two segments: Evernorth Health Services (pharmacy benefit management, specialty pharmacy, and care services) and Cigna Healthcare (commercial medical plans and international health). On March 19, 2025, the company completed the sale of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plan, and supplemental benefits businesses to Health Care Service Corporation. Individual and family plan offerings are currently available in 11 states.
Evernorth Health Services — anchored by the Express Scripts pharmacy benefit brand and Accredo Specialty Pharmacy (35 licensed pharmacies) — earns fees from processing pharmacy benefit claims, managing drug formularies and rebates, and distributing specialty pharmaceuticals through CuraScript SD (four distribution centers). Three clients each drive significant Evernorth revenues: Centene Corporation under a multiyear agreement from January 1, 2024; Prime Therapeutics; and TRICARE, the U.S. Department of Defense military health care program. Evernorth sources roughly half of pharmaceutical purchases from a single wholesaler, with backup contracts available from other wholesalers. Cigna Healthcare generates premiums and ASO fees from employer medical plans, individual and family plans, and international health coverage; ASO arrangements represented approximately 32% of 2025 Cigna Healthcare segment revenues, covering 79% of Cigna Healthcare medical customers. The 10 largest retail pharmacy chains represent approximately 47% of total stores in Cigna's largest pharmacy network.
Show full overview
Evernorth announced a rebate-free pharmacy benefit model that Cigna Healthcare's fully insured customers plan to adopt from 2027, with all Evernorth Health Services clients intending to transition to the new standard model from 2028. The Inflation Reduction Act granted CMS authority to negotiate prices for high-cost Medicare Part D and Part B drugs; the 10-K notes drug companies may adjust broader market pricing strategies in response, which could affect formulary rebate economics. If pharmaceutical manufacturers reduce rebates during the transition to the rebate-free model, pharmacy benefit segment margins could be affected, depending on how quickly the new model gains client adoption.
See also: Healthcare · Healthcare Plans
From The Cigna Group's most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-08-15Recent Developments — The Cigna Group
Latest news
- NEWS Cigna Group stock outperforms competitors despite losses on the day - MarketWatch — MarketWatch positive
- NEWS Cigna Group stock outperforms competitors despite losses on the day - marketwatch.com — marketwatch.com positive
- NEWS Cigna (CI) Reports Earnings Tomorrow: What To Expect - StockStory — StockStory neutral
- NEWS Cigna Beat Earnings and Raised Guidance. Why the Stock Is Dropping. - Barron's — Barron's positive
- NEWS Cigna Beat Earnings and Raised Guidance. Why the Stock Is Dropping. - barrons.com — barrons.com positive
Generated 2026-08-15T13:12:18Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMSupplierone wholesaler10-K Item 1: 'Evernorth Health Services uses one wholesaler for approximately half of our pharmaceutical purchases'
- MEDIUMCustomerCentene Corporation10-K Item 1: 'three clients that each drive significant revenues ... Express Scripts and Centene Corporation ("Centene") have a multiyear agreement'
- MEDIUMCustomerPrime Therapeutics10-K Item 1: 'three clients that each drive significant revenues ... Express Scripts and Prime Therapeutics LLC ("Prime") have agreements'
- MEDIUMCustomerTRICARE10-K Item 1: 'three clients that each drive significant revenues ... The Department of War (previously the Department of Defense) TRICARE® is the military health care program'
- MEDIUMcounterparty10 largest retail pharmacy chains10-K Item 1A: 'The 10 largest retail pharmacy chains represent approximately 47% of the total number of stores in our largest network'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $282.56, but acceptable to hold if already in. Reasons: Thin upside margin: 8.7%; Negative momentum. Chart setup: RSI 44 mid-range, Bollinger mid-band. Mixed signals. Hold existing position. Target $307.27 (+8.7%), stop $265.02 (−6.6%), A.R:R 1.3:1. Score 5.6/10, moderate confidence.
Take-profit target: $307.27 (+8.7% upside). Target $307.27 (+8.7%), stop $265.02 (−6.6%), A.R:R 1.3:1. Stop-loss: $265.02.
Thin upside margin: 8.7%; Negative momentum.
The Cigna Group trades at a P/E of 11.7 (forward 8.4). TrendMatrix value score: 8.2/10. Verdict: Hold.
34 analysts cover CI with a consensus score of 4.1/5. Average price target: $341.
What does The Cigna Group do?The Cigna Group runs two segments: Evernorth Health Services (pharmacy benefit management, specialty pharmacy, care...
The Cigna Group runs two segments: Evernorth Health Services (pharmacy benefit management, specialty pharmacy, care services) and Cigna Healthcare (commercial medical plans, international health), serving 185 million customer relationships. Revenue comes from pharmacy processing fees, insurance premiums, drug dispensing margins, and ASO fees across more than 30 markets as of December 31, 2025.